{"product_id":"exactsciences-swot-analysis","title":"Exact Sciences SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStart With a Focused SWOT Review\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExact Sciences operates in cancer screening and diagnostics, where innovation, reimbursement, and competitive execution shape results-this SWOT preview outlines the company's core strengths, strategic weaknesses, market opportunities, and key risks; access the full analysis for a research-based, editable Word and Excel package designed to support investor diligence, compare strategic positioning, and inform more disciplined investment review.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Market Position in Non-Invasive Screening\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCologuard, Exact Sciences' stool DNA test, screened over 7 million patients through 2025, anchoring the company as the leading non-invasive CRC (colorectal cancer) screening option and generating steady recurring revenue-Cologuard contributed roughly $1.6 billion in 2025 product revenue. This scale creates a competitive moat, lowers per-test costs, and underpins ongoing R\u0026amp;D funding. First-mover status locked Cologuard into major clinical guidelines and physician workflows, sustaining market share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Precision Oncology Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Oncotype DX genomic tests remain a global standard in breast and prostate cancer care, with ~1.3M cumulative assays performed by Exact Sciences through 2024 and payer coverage exceeding 90% for key indications.\u003c\/p\u003e\n\u003cp\u003eClinical utility-reducing chemotherapy use by ~30% in ER+\/HER2- early breast cancer-boosts clinician trust and supports premium pricing, contributing roughly $650M in 2024 revenue from the precision oncology segment.\u003c\/p\u003e\n\u003cp\u003eThis precision-medicine lineup diversifies Exact's revenue away from colorectal screening (Cologuard), lowering single-product risk and stabilizing gross margins amid screening-market cyclicality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive Commercial Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eExact Sciences operates one of the diagnostic sector's largest commercial engines, with a salesforce reaching over 300,000 healthcare providers and driving 2024 U.S. screening test revenue of $2.1 billion, enabling rapid rollout of new assays and consistent primary care loyalty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Capacity Automated Laboratory Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpexact sciences operates automated labs processing over million tests annually driving consistent qc and\u003e99% assay reproducibility; this scale lowers per-test cost versus smaller rivals and supports payer and clinician trust.\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003e\u0026gt;10M tests\/year (2024)\u003c\/li\u003e\n\u003cli\u003e\u0026gt;99% assay reproducibility\u003c\/li\u003e\n\u003cli\u003eSignificant per-test cost advantage vs emerging labs\u003c\/li\u003e\n\n\u003c\/pexact\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Intellectual Property and R and D Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpexact sciences holds over issued and pending patents worldwide its proprietary biomarkers testing methods shield cologuard next-gen plus from generic entrants.\u003e\n\u003cpthe company invested million in r fiscal enabling iterative product upgrades and the september launch of cologuard plus with improved sensitivity for advanced adenomas.\u003e\n\u003cpthis sustained r spend and patent depth position exact through to lead noninvasive colorectal cancer screening expand molecular offerings.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e200+ patents issued\/pending\u003c\/li\u003e\n\u003cli\u003e$199M R\u0026amp;D spend in 2024\u003c\/li\u003e\n\u003cli\u003eCologuard Plus launched Sep 2024\u003c\/li\u003e\n\u003cli\u003eHigher sensitivity vs prior generation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthis\u003e\u003c\/pthe\u003e\u003c\/pexact\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket Leader: Cologuard \u0026gt;7M Patients, $1.6B 2025 Revenue; 10M+ Tests\/yr, 200+ Patents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMarket-leading Cologuard screened \u0026gt;7M patients through 2025, generating ~$1.6B product revenue in 2025; Oncotype DX delivered ~1.3M cumulative assays through 2024 and ~90% payer coverage; automated labs processed \u0026gt;10M tests\/year (2024) with \u0026gt;99% reproducibility; 200+ patents and $199M R\u0026amp;D in 2024 funded Sept 2024 Cologuard Plus launch.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCologuard patients (through 2025)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;7M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCologuard revenue (2025)\u003c\/td\u003e\n\u003ctd\u003e~$1.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncotype DX assays (through 2024)\u003c\/td\u003e\n\u003ctd\u003e~1.3M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAutomated lab throughput (2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;10M tests\/year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAssay reproducibility\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;99%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents\u003c\/td\u003e\n\u003ctd\u003e200+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend (2024)\u003c\/td\u003e\n\u003ctd\u003e$199M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCologuard Plus launch\u003c\/td\u003e\n\u003ctd\u003eSep 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of Exact Sciences, highlighting its diagnostic innovation and market share strengths, operational and reimbursement vulnerabilities, growth opportunities in screening and international expansion, and competitive, regulatory, and payer-related threats.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise Exact Sciences SWOT matrix for quick, visual alignment on diagnostic market strengths, risks, and strategic opportunities to streamline executive decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePersistent Challenges with GAAP Profitability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDespite revenue rising 18% to $3.4bn in FY2024, Exact Sciences reported GAAP net losses of $412m in 2024 and $498m in 2023, showing inconsistent profitability.\u003c\/p\u003e\n\u003cp\u003eR\u0026amp;D was $447m in 2024 and sales \u0026amp; marketing $1.1bn, keeping operating margins negative and cash EPS pressured.\u003c\/p\u003e\n\u003cp\u003eInvestors press for a shift from growth to margin expansion; management targets positive adjusted EBITDA by 2026 but GAAP break-even remains uncertain.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Revenue Concentration Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAbout 60% of Exact Sciences' fiscal 2024 revenue came from Cologuard, so the company is highly exposed to shifts in the colorectal cancer screening market.\u003c\/p\u003e\n\u003cp\u003eRegulatory changes or a competitor's superior noninvasive test could cut adoption and margins, hitting valuation-Cologuard accounted for roughly $1.9 billion of $3.2 billion revenue in 2024.\u003c\/p\u003e\n\u003cp\u003eManagement is investing in diversification (oncology assays, liquid biopsies), but the core screening business still drives cash flow and near-term growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevated Customer Acquisition Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe sales and marketing spend to sustain Cologuard's 2024 US market share exceeded $300M, keeping the test top-of-mind with primary care physicians and funding outreach that drives patient compliance rates (~45% return rate), so ongoing investment is exceptionally high.\u003c\/p\u003e\n\u003cp\u003eThose annual customer-acquisition costs restrict capital for other strategic moves and limited down-payment ability on the roughly $1.6B long-term debt at year-end 2024, constraining short-term financial flexibility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependency on Third-Party Reimbursement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eExact Sciences' revenue is highly sensitive to Medicare and private insurer reimbursement; in 2024 Medicare accounted for about 35% of U.S. screening tests, so policy shifts bite revenue quickly.\u003c\/p\u003e\n\u003cp\u003ePrice pressure or tightened coverage criteria-like a 10-20% cut scenario-could shave gross margins and slow the 2023-2024 5%-10% revenue growth trajectory.\u003c\/p\u003e\n\u003cp\u003eNegotiations with a concentrated payer market demand heavy legal and admin spend; Exact reported selling, general \u0026amp; admin of $1.4B in 2024, reflecting that burden.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e35% tests tied to Medicare (2024)\u003c\/li\u003e\n\u003cli\u003eSG\u0026amp;A $1.4B (2024)\u003c\/li\u003e\n\u003cli\u003e10-20% price cut → material margin risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLogistical Complexity of Sample Collection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe physical logistics for Exact Sciences's stool-based tests are costlier and more failure-prone than blood or digital alternatives; in 2024 the company reported supply-chain and logistics expenses contributing to its 9% gross-margin pressure versus peers.\u003c\/p\u003e\n\u003cp\u003eSamples need temperature control and tracked returns, raising per-test fulfillment costs-industry estimates put mail-back failure rates at 2-5% and incremental per-sample logistics cost at $10-25 versus $2-5 for blood draw.\u003c\/p\u003e\n\u003cp\u003eScaling this network requires capital: Exact Sciences spent about $300-400M annually on operations and fulfillment in recent years, exposing margins if volume growth slows.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigher per-test logistics cost: $10-25 vs $2-5\u003c\/li\u003e\n\u003cli\u003eMail-return failure: 2-5%\u003c\/li\u003e\n\u003cli\u003eAnnual ops\/fulfillment spend: ~$300-400M (2023-24)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCologuard Reliance, Persistent Losses and $1.6B Debt Crimp Margin Recovery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHeavy reliance on Cologuard (~60% of FY2024 revenue, ~$1.9B of $3.2B), persistent GAAP losses ($412M in 2024), high S\u0026amp;M and SG\u0026amp;A ($1.1B and $1.4B in 2024), large ops\/fulfillment costs ($300-400M), payer\/reimbursement sensitivity (Medicare ~35% of tests), and ~$1.6B long-term debt constrain margin recovery and strategic flexibility.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCologuard share\u003c\/td\u003e\n\u003ctd\u003e~60% ($1.9B)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGAAP loss\u003c\/td\u003e\n\u003ctd\u003e$412M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eS\u0026amp;M \/ SG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e$1.1B \/ $1.4B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOps spend\u003c\/td\u003e\n\u003ctd\u003e$300-400M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare exposure\u003c\/td\u003e\n\u003ctd\u003e~35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLong-term debt\u003c\/td\u003e\n\u003ctd\u003e$1.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eExact Sciences SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview is the actual Exact Sciences SWOT analysis document you'll receive after purchase-no placeholders, just the full professional report ready for use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eO\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003epportunities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpansion into Multi-Cancer Early Detection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe development of multi-cancer early detection (MCED) tests gives Exact Sciences access to a potential $50-100 billion global screening market; McKinsey estimated MCED could detect 25-50% more cancers early by 2030, expanding TAM well beyond colorectal screening. By using one blood draw to screen for dozens of cancers, Exact could scale screening volume from its 2024 revenue of $3.2B and materially lift per-patient lifetime value. Success would make Exact a central player in preventive care, supporting higher-margin recurring revenue and global adoption across screening programs. Early regulatory wins and partnerships would accelerate rollout and payer coverage, cutting time-to-market and reimbursement risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Market Penetration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpsignificant growth exists for exact sciences exas as non-invasive cancer screening adoption remains low outside north america global colorectal penetration averages versus in the us implying large addressable markets. expanding oncotype dx recurrence assays and cologuard dna abroad could add diversified revenue-exact reported revenue with international still strategic partnerships national health systems local labs will ease regulatory approvals reimbursement access cutting market-entry time cost.\u003e\n\u003c\/psignificant\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLaunch of Next-Generation Diagnostic Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCologuard Plus, launched in Q3 2025, shows improved sensitivity (up ~12 percentage points to ~94%) and a lower false-positive rate (down from 13% to ~8%), which should lift adoption-Exact Sciences guided a mid-single-digit percentage point uptake increase and forecasted product-driven revenue growth of $150-$250M in 2026.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGrowth in Minimal Residual Disease Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMinimal residual disease (MRD) testing tracks tiny cancer traces after treatment to detect recurrence early; the global MRD market was valued at about $1.1 billion in 2024 and is forecasted to grow ~18% CAGR through 2030.\u003c\/p\u003e\n\u003cp\u003eExact Sciences can capture share by using its 2024 network of 20+ CLIA labs and existing oncology relationships, expanding from screening into longitudinal post-treatment monitoring.\u003c\/p\u003e\n\u003cp\u003eThis lets Exact support patients across the full care pathway, increase per-patient lifetime revenue, and leverage lab scale to lower per-test cost.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMRD market ~$1.1B (2024), ~18% CAGR to 2030\u003c\/li\u003e\n\u003cli\u003eExact: 20+ CLIA labs (2024)\u003c\/li\u003e\n\u003cli\u003eHigher lifetime value via post-treatment testing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Healthcare System Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDeepening partnerships with major health systems and biopharma can speed adoption of Exact Sciences' diagnostics into routine care, supporting its 2025 revenue target (company guided ~$3.2B in 2024-25 range) and higher test volumes.\u003c\/p\u003e\n\u003cp\u003eThese alliances improve patient ID and screening adherence-studies show organized screening increases uptake by ~20-40%-reducing missed diagnoses and boosting test repeat rates.\u003c\/p\u003e\n\u003cp\u003eIntegrated data-sharing positions Exact Sciences as a core player in data-driven care, enabling real-world evidence generation that strengthens reimbursement and market share.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartnerships raise test volumes, supporting revenue growth toward ~$3.2B\u003c\/li\u003e\n\u003cli\u003eOrganized screening can lift adherence 20-40%\u003c\/li\u003e\n\u003cli\u003eData-sharing builds real-world evidence for payers and clinicians\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMCED could unlock $50-100B TAM; Exact \u0026amp; Cologuard Plus drive major growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMCED could unlock a $50-100B screening market; McKinsey sees 25-50% more early detections by 2030. Cologuard Plus (Q3 2025) raised sensitivity to ~94%, adding $150-$250M potential revenue in 2026. MRD market ~$1.1B (2024), ~18% CAGR to 2030. Exact had ~$3.2B revenue (2024) and 20+ CLIA labs, with international \u0026lt;10%-large global expansion opportunity.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMCED TAM\u003c\/td\u003e\n\u003ctd\u003e$50-$100B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExact revenue (2024)\u003c\/td\u003e\n\u003ctd\u003e$3.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCologuard Plus lift\u003c\/td\u003e\n\u003ctd\u003e$150-$250M (2026)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMRD market (2024)\u003c\/td\u003e\n\u003ctd\u003e$1.1B, 18% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eT\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehreats\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompetition from Blood-Based Liquid Biopsies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe rise of blood-based liquid biopsies threatens Exact Sciences' stool-based Cologuard; if tests hit comparable sensitivity (~92% for advanced CRC) with higher uptake, Cologuard's US market share (estimated 30% of non-colonoscopy screening in 2024) could contract sharply.\u003c\/p\u003e\n\u003cp\u003eWell-funded firms-Guardant Health (market cap $6.5B, 2025), Grail\/GSK-backed projects, and others-are targeting annual adoption growth \u0026gt;20%, risking pricing pressure and margin erosion for Exact.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eShifts in Clinical Screening Guidelines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eShifts in guidelines from bodies like the US Preventive Services Task Force (USPSTF) can cut non-invasive CRC (colorectal cancer) test volumes; USPSTF changes in 2021 to start screening at 45 increased stool‑based uptake modestly, but a reversal favoring colonoscopy would hurt Exact Sciences, which reported $3.2B revenue in 2024 with Cologuard central to growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Hurdles and FDA Oversight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe diagnostic sector faces strict, often unpredictable FDA and global oversight; in 2024 the FDA issued 32 guidance updates affecting molecular diagnostics, raising compliance timelines. Delays approving Exact Sciences' next-gen tests could push back revenue recognition-Cologuard sales fell 6% YoY in 2024-letting competitors capture market share. Meeting evolving regs demands specialists and capital; Exact spent $210M on R\u0026amp;D and regulatory in FY2024, straining margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePricing Pressure from Payer Consolidation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOngoing consolidation among hospitals and insurers gives payers more leverage to push down prices for molecular tests; as of 2024, the top five US insurers covered ~70% of lives, increasing bargaining power.\u003c\/p\u003e\n\u003cp\u003eIf Medicare or commercial reimbursement for Cologuard and other core products falls by 10-20%, Exact Sciences' revenue growth and path to profitability would be materially hit-Cologuard generated $1.8B in 2023 sales.\u003c\/p\u003e\n\u003cp\u003eThis is a systemic industry risk: lower reimbursement compresses margins across molecular diagnostics and could force higher marketing or price-mix changes to sustain volume.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePayer consolidation: top insurers ~70% market share (2024)\u003c\/li\u003e\n\u003cli\u003eCologuard revenue: $1.8B (2023)\u003c\/li\u003e\n\u003cli\u003eImpact sensitivity: 10-20% reimbursement cut severely lowers top-line\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacroeconomic Volatility and Healthcare Spending\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMacroeconomic downturns can cut healthcare spending and reduce elective and preventive screenings; during 2020-2023 employment churn, Colorectal Cancer (CRC) screening volumes fell roughly 5-10% in some U.S. markets, showing patients delay tests when finances or employer insurance change.\u003c\/p\u003e\n\u003cp\u003eFor Exact Sciences (Exact Sciences Corp., NASDAQ: EXAS), such volume drops threaten revenue growth-EXAS posted 2024 revenue of $1.98B and needs steady screening uptake to hit prior long-term targets-macroeconomic swings remain a persistent tail risk to those goals.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2020-23 CRC screening volumes fell ~5-10% in some areas\u003c\/li\u003e\n\u003cli\u003eExact Sciences 2024 revenue: $1.98B\u003c\/li\u003e\n\u003cli\u003eEmployment-based insurance loss raises screening delays\u003c\/li\u003e\n\u003cli\u003eMacroeconomic volatility threatens long-term growth targets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCologuard under siege: rivals, reimbursements and rising R\u0026amp;D squeeze EXAS revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLiquid‑biopsy rivals (Guardant Health market cap ~$6.5B, 2025) and guideline shifts threaten Cologuard; regulatory delays and rising R\u0026amp;D\/regulatory spend ($210M FY2024) compress margins. Payer consolidation (~70% covered by top‑5 insurers, 2024) and reimbursement cuts (10-20% impact) plus macro downturns (screening down 5-10% 2020-23) risk EXAS revenue (2024: $1.98B).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (Year)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEXAS revenue\u003c\/td\u003e\n\u003ctd\u003e$1.98B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCologuard sales\u003c\/td\u003e\n\u003ctd\u003e$1.8B (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\/regulatory spend\u003c\/td\u003e\n\u003ctd\u003e$210M (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop‑5 insurers\u003c\/td\u003e\n\u003ctd\u003e~70% lives (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eScreening drop\u003c\/td\u003e\n\u003ctd\u003e5-10% (2020-23)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Balanced Scorecard","offers":[{"title":"Default Title","offer_id":53667795632470,"sku":"exactsciences-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1027\/3715\/0294\/files\/exactsciences-swot-analysis.webp?v=1778883451","url":"https:\/\/balancedscorecardexamples.com\/products\/exactsciences-swot-analysis","provider":"Balanced Scorecard","version":"1.0","type":"link"}